newsfilter
← Latest News
PR Newswire·

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

  • BioArctic AB issued 5,000 Class B shares in May 2026 via the exercise of 5,000 stock options from the 2019/2028 program.
  • As of May 29, 2026, BioArctic AB had a total of 88,724,485 shares outstanding.
  • The share capital consists of 74,324,489 listed Class B shares (one vote per share) and 14,399,996 unlisted Class A shares (ten votes per share).
  • The total voting power in the company amounts to 218,324,449 votes.
  • BioArctic AB is a Swedish biopharma firm focused on neurodegenerative diseases, notably co-developing Leqembi® for Alzheimer's with Eisai.
  • The company utilizes its proprietary BrainTransporter™ technology to enhance antibody delivery across the blood-brain barrier.
  • This disclosure was released on May 29, 2026, at 6:30 pm CET to comply with the EU Market Abuse Regulation.